Organization type

  • Material supplier
  • Service provider

Early phases

  • Biomarker identification
  • Omics
    • Epigenomics
    • Genomics
    • Metabolomics
    • Phenomics
    • Proteomics
    • Transcriptomics
  • Systems biology
  • Target identification – new biological hypothesis
  • Target validation – Hypothesis verification

Screening

  • Assay development
    • In vitro screening models
    • In vivo screening models
  • Screening and high throughput screening using small molecules (including natural product, DNA encoded libraries and fragment libraries)

Optimization phases

  • In vitro biochemical models(including assay/model development and testing)
  • In vitro cellular and organotypic 3D models (including assay/model development and testing)
  • Mechanism of action (MoA) assessment
    • Functional cellular panels
    • Omics profiling
    • Selectivity panels
    • Target deconvolution

Functional areas

  • Material / reagents supply
  • Molecular and cellular biology
    • Cell line generation
    • Flow cytometry
    • Gene editing
    • Imaging / High content screening
    • Mechanistic enzymology & receptorology
    • Protein expression / purification
    • qPCR
    • Sequencing
  • Structural biology

Terapeutic areas

  • Autoimmunity / Inflammation
  • Blood and lymphatic system
  • Cancer
  • Cardiovascular
  • Dermatology
  • Infectious diseases
  • Metabolism / Endocrinology
  • Nervous Central System
  • Rare diseases

Additional activities

  • CROs providing no-regulatory and regulatory services for drug discovery
  • Industry associations